
JPXHealthcareMedical - Instruments & Supplies
最新数据
JP¥1,316
+JP¥9.00 · +0.69%
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.
最新数据
JP¥1,316
+JP¥9.00 · +0.69%
盘中时间采用JST。市场数据可能有所延迟。
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.
日内区间
当前JP¥1,316
52周区间
当前JP¥1,316
盘中时间采用JST。市场数据可能有所延迟。
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.
日内区间
当前JP¥1,316
52周区间
当前JP¥1,316
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(JPY) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6605.38亿 JPY | 6445.86亿 JPY | 5867.85亿 JPY | 5451.99亿 JPY | 4947.89亿 JPY |
| 销货成本 | 4522.56亿 JPY | 4509.27亿 JPY | 4128.07亿 JPY | 3792.97亿 JPY | 3429.51亿 JPY |
| 毛利 | 2082.82亿 JPY | 1936.59亿 JPY | 1739.78亿 JPY | 1659.02亿 JPY | 1518.38亿 JPY |
| 研究与开发 | — | 216.66亿 JPY | 208.46亿 JPY | 196.69亿 JPY | 187.34亿 JPY |
| 销售、一般及管理费用 | 1706.57亿 JPY | 1453.94亿 JPY | 1307.97亿 JPY | 1285.03亿 JPY | 1092.2亿 JPY |
| 营业费用 | 1706.57亿 JPY | 1670.6亿 JPY | 1516.43亿 JPY | 1481.72亿 JPY | 1279.54亿 JPY |
| 利息收入 | 22.14亿 JPY | 21.83亿 JPY | 15.76亿 JPY | 10.96亿 JPY | 6.69亿 JPY |
| 利息支出 | 97.65亿 JPY | 78.44亿 JPY | 65.27亿 JPY | 45.01亿 JPY | 41.89亿 JPY |
| 折旧和摊销 | 637.37亿 JPY | 656.48亿 JPY | 588.72亿 JPY | 487.43亿 JPY | 461.64亿 JPY |
| 营业利润 | 376.25亿 JPY | 265.99亿 JPY | 223.35亿 JPY | 177.3亿 JPY | 238.84亿 JPY |
| 净利润 | 135.04亿 JPY | 51.14亿 JPY | 111.09亿 JPY | 45.75亿 JPY | 134.55亿 JPY |
公司数据更新于 2026年10月5日。
近期已公布业绩
近期已公布业绩
年度分割调整后的每股现金分配。
JP¥23.00
2025年(完整年度)-25.8% 自从 2021
2026年(部分年度):JP¥31.00
JP¥31.00
2,021
JP¥26.00
2,022
JP¥18.50
2,023
JP¥27.00
2,024
JP¥23.00
2,025
JP¥31.00
2,026*
* 在现有股息历史记录中,该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息即将实施 | 2027年3月30日 | JP¥20.00Semi-Annual | 2027年3月31日 | 2027年3月30日 |
股息 | 2026年9月29日 | JP¥12.00Semi-Annual | 2026年9月30日 | 2026年9月29日 |
股息 | 2026年3月30日 | JP¥19.00Semi-Annual | 2026年3月31日 | 2026年6月10日 |
股息 | 2025年9月29日 | JP¥10.00Semi-Annual | 2025年9月30日 | 2025年12月10日 |
股息 | 2025年3月28日 | JP¥13.00Semi-Annual | 2025年3月31日 | 2025年6月27日 |
股息 | 2024年9月27日 | JP¥12.00Semi-Annual | 2024年9月30日 | 2024年12月9日 |
除息 2027年3月30日
JP¥20.00
Semi-Annual
2027年3月31日登记 · 支付日 2027年3月30日
除息 2026年9月29日
JP¥12.00
Semi-Annual
2026年9月30日登记 · 支付日 2026年9月29日
除息 2026年3月30日
JP¥19.00
Semi-Annual
2026年3月31日登记 · 支付日 2026年6月10日
除息 2025年9月29日
JP¥10.00
Semi-Annual
2025年9月30日登记 · 支付日 2025年12月10日
除息 2025年3月28日
JP¥13.00
Semi-Annual
2025年3月31日登记 · 支付日 2025年6月27日
除息 2024年9月27日
JP¥12.00
Semi-Annual
2024年9月30日登记 · 支付日 2024年12月9日
AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。